Drugs / NESOLICAFTOR
NESOLICAFTOR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03251092 | Jul 2017 → Dec 2019 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT03258424 Comparator | Jul 2017 → Oct 2018 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02846142 Comparator | Jun 2016 → Mar 2017 | — | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03500263 Comparator | Jan 2018 → Mar 2019 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02718495 Comparator | Jul 2016 → Nov 2017 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03591094 Comparator | Aug 2018 → Feb 2019 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NESOLICAFTOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297479 ↗ |
| Known as | Nesolicitor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297479 ↗ |
| Known as | PTI-428 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02718495 ↗ |
| Modality | Small molecule | — CHEMBL4297479 ↗ |
| Route | Oral | “once daily oral doses of PTI-428 or placebo” NCT03591094 ↗ |